Department of Psychiatry, University of Calgary, Alberta, Canada.
START Clinic for Mood and Anxiety Disorders, Toronto, Ontario, Canada.
Int J Neuropsychopharmacol. 2018 Feb 1;21(2):128-144. doi: 10.1093/ijnp/pyx081.
Major depressive disorder is an often chronic and recurring illness. Left untreated, major depressive disorder may result in progressive alterations in brain morphometry and circuit function. Recent findings, however, suggest that pharmacotherapy may halt and possibly reverse those effects. These findings, together with evidence that a delay in treatment is associated with poorer clinical outcomes, underscore the urgency of rapidly treating depression to full recovery. Early optimized treatment, using measurement-based care and customizing treatment to the individual patient, may afford the best possible outcomes for each patient. The aim of this article is to present recommendations for using a patient-centered approach to rapidly provide optimal pharmacological treatment to patients with major depressive disorder. Offering major depressive disorder treatment determined by individual patient characteristics (e.g., predominant symptoms, medical history, comorbidities), patient preferences and expectations, and, critically, their own definition of wellness provides the best opportunity for full functional recovery.
重度抑郁症是一种常见的慢性、反复发作的疾病。如果不加以治疗,重度抑郁症可能导致大脑形态计量学和回路功能的进行性改变。然而,最近的研究结果表明,药物治疗可能会阻止并可能逆转这些影响。这些发现,以及治疗延迟与较差的临床结果相关的证据,凸显了迅速治疗抑郁症以达到完全康复的紧迫性。使用基于测量的护理和根据个体患者定制治疗的早期优化治疗,可能为每位患者提供最佳的治疗效果。本文的目的是提出建议,采用以患者为中心的方法,为重度抑郁症患者迅速提供最佳的药物治疗。根据个体患者的特征(例如,主要症状、病史、合并症)、患者的偏好和期望,以及至关重要的是他们自己对健康的定义来提供治疗,为全面功能恢复提供了最佳机会。